What to know about GAMMAGARD LIQUID

Effectiveness and
side effects with
IV infusions

IV infusions: Study results

There was a clinical study with IV infusions that 61 patients participated in. Of those PI (primary immunodeficiency) patients, GAMMAGARD LIQUID was shown to be effective at a dose of 300 to 600 mg/kg every 3 to 4 weeks for 12 months. 

In the study, those taking GAMMAGARD LIQUID experienced the following per patient-year*:

Acute serious bacterial infection icon.

0 acute serious
bacterial infections†

Hospital icon.

0 hospitalizations
because of an infection

Bacteria icon.

4 validated other bacterial
infections reported‡

*A patient-year is a patient experience in a clinical trial over the course of 1 year.

Validated acute serious bacterial infections (ASBIs).

The validated other bacterial infections were urinary tract infection (1), gastroenteritis (sometimes called “stomach flu”) (1), and ear infection (2).

What kind of side effects have people experienced?

95% icon.

95% of the non-serious side effects were considered mild to moderate

381 of the 400 non-serious side effects reported in patients treated with GAMMAGARD LIQUID IV were considered mild (217) to moderate (164). The remaining 5% (19) were severe.

5.2% icon.

5.2% rate of headache per infusion

Headaches were the most common side effect (94 of 1,812 infusions).

Side effects may occur with an IV treatment, and they are more likely to occur when you are being treated for the first time or receiving a new medicine. In the clinical trial, the most common side effects with IV infusions of GAMMAGARD LIQUID seen in ≥5% of the patients were headache, fatigue, fever, nausea, chill/shaking chills, pain in the hands or feet, diarrhea, migraine, dizziness, vomiting, cough, hives, asthma, sore throat, rash, joint pain, muscle pain, swelling in the arms or legs, itching, and heart murmur.